Comparison of the diagnostic power of serum circulating miR-21, VEGF, and CA15-3 in breast cancer
-
By
-
Hang Li
-
Qian Li
-
Xiaojing Tie
-
Feng Ji
-
LiNa Ma
-
Chunyan Ma
-
May 28, 2026
-
Clinical Scorecard: Evaluation of Serum Levels of miR-21, VEGF, and CA15-3 for Breast Cancer Diagnosis
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | miR-21 as a regulator of VEGF pathway and tumor progression (source needed). |
| Target Population | |
| Care Setting | |
Key Highlights
- Serum miR-21 levels significantly elevated in breast cancer patients compared to healthy controls (source needed).
- miR-21 demonstrated sensitivity (81.10%) and specificity (98.40%) for breast cancer diagnosis (source needed).
Guideline-Based Recommendations
Diagnosis
- Consider serum miR-21 levels for early breast cancer detection (source needed).
Management
Monitoring & Follow-up
Risks
- Limitations include small sample size and single-center design (source needed).
Patient & Prescribing Data
miR-21 may help distinguish benign from malignant lesions (source needed).
Clinical Best Practices
- Incorporate miR-21 testing in diagnostic protocols for breast cancer.
Related Resources & Content
